Search results
Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration
Benzinga via AOL· 18 hours agoAfter topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co...
Merck stock target raised on strong Q1 results By Investing.com
Investing.com· 7 days agoOn Friday, Wells Fargo adjusted its outlook on shares of pharmaceutical giant Merck & Co., Inc....
Merck's KEYTRUDA shows survival benefit in gastric cancer trial By Investing.com
Investing.com· 2 days agoMerck & Co., Inc., a leading pharmaceutical company, announced positive results from the Phase 3...
Merck KGaA's Dividend Analysis
GuruFocus.com via Yahoo Finance· 4 days agoMerck KGaA (MKKGY) recently announced a dividend of $0.47 per share, payable on 2024-05-09, with the ex-dividend date set for 2024-04-29. As investors...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 8 minutes agoThe MASH space has heated up with the FDA approval of the first-ever treatment, a drug called...
The top pharmaceutical companies by R&D expenditure
Pharmaceutical Technology via Yahoo Finance· 1 day agoLast year, major pharmaceutical companies heavily invested in R&D, with expenditure ranging from around 14% to 50% of their revenues. Some of the...
Top 20 biopharma kick off 9.6% market cap surge in Q1 2024 amid Medicare price talks
Pharmaceutical Technology via Yahoo Finance· 7 days agoDespite these uncertainties, companies are bolstering their portfolios to address impending patent...
Cantor Fitzgerald Brokers Boost Earnings Estimates for Merck & Co., Inc. (NYSE:MRK)
ETF DAILY NEWS· 3 days agoMerck & Co., Inc. (NYSE:MRK – Free Report) – Equities research analysts at Cantor Fitzgerald increased their FY2024 earnings per share (EPS) estimates for shares of
Merck reports promising V116 vaccine trial results By Investing.com
Investing.com· 4 days agoMerck & Co. (NYSE: MRK) has presented new data from its Phase 3 STRIDE-10 trial of V116, an...
Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y
Zacks via Yahoo Finance· 22 hours agoThe company usually earns collaboration revenues from agreements with several big pharma/biotech...